about
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular CarcinomaMortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (≤15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data.Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes.Transplant-induced reactivation of murine cytomegalovirus immediate early gene expression is associated with recruitment of NF-κB and AP-1 to the major immediate early promoter.Comparative top down proteomics of peripheral blood mononuclear cells from kidney transplant recipients with normal kidney biopsies or acute rejection.Functional Maturation of Induced Pluripotent Stem Cell Hepatocytes in Extracellular Matrix-A Comparative Analysis of Bioartificial Liver Microenvironments.Exome Sequencing and Prediction of Long-Term Kidney Allograft Function.Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample.Proteoforms in Peripheral Blood Mononuclear Cells as Novel Rejection Biomarkers in Liver Transplant Recipients.Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Technical Considerations.(90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes.Orthogonal Comparison of Molecular Signatures of Kidney Transplants With Subclinical and Clinical Acute Rejection: Equivalent Performance Is Agnostic to Both Technology and Platform.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.The impact of coronary artery disease on outcomes after liver transplantation.Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.Medication understanding, non-adherence, and clinical outcomes among adult kidney transplant recipients.Emerging Ethical Considerations of Donation After Circulatory Death: Getting to the Heart of the Matter.Changes in Urinary Microbiome Populations Correlate in Kidney Transplants With Interstitial Fibrosis and Tubular Atrophy Documented in Early Surveillance Biopsies.Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation.Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience.A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score.Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort.Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.ReplyResponse to “Shifting the conversation on outcomes reporting”A Surgeon's Guide to Bundled Payment Models for Episodes of CareBehavioral Screening and Intervention for Improving Lower-Extremity Arthroplasty Outcomes and Controlling Costs-ReplyThe "opportunity costs" of kidney transplantationCaveat emptor: the devil is still in the detailUse of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting reportClinical implications for the use of a biomarker for subclinical rejection - Conflating arguments cause a disconnection between the premise and the conclusionA clinically relevant murine model unmasks a "two-hit" mechanism for reactivation and dissemination of cytomegalovirus after kidney transplant
P50
Q28314897-6BA88347-5511-451D-9037-D12F5922122DQ31164899-C9CCE1F1-E4F4-40B5-AEE4-571A5E7B7326Q33885388-32E70D75-FC1E-40A0-BC0E-35D14388DDDBQ36862292-CF7008B4-F24F-42A9-B35E-5BE05F4F11EFQ37116032-8D248576-A1C0-42F8-BA2B-1DEC9CBA7B3DQ37200883-73919B09-0921-456E-B37C-268156C8CCE3Q37297025-7CF3AD5A-DB9E-4F1B-8D26-F2C2C0B40809Q37562126-D5533A94-B902-4A16-8D99-7B78E834A86CQ38433502-67F246C7-2048-483E-B011-0BCEBD2E8C8FQ38782485-A678589C-AF4F-4146-8454-C8EA7629CA26Q38877624-018EED87-D3E2-4CE1-8161-9544204244F3Q38966321-B655B280-BD52-4F42-B45B-0C31C09D5476Q40091767-F30FEA1E-2421-4BFC-87EC-784EF03DAF07Q40516493-46BACD86-4E4F-45B1-BF38-630CD193715AQ40821228-75A7E85E-00D1-4B5F-93D6-01EA3B8CD844Q41638097-CCCC18C1-CF0F-445D-9FF7-DF09FA25A33AQ44484256-ECABD14D-54E0-48D0-8D32-CEDB2A805C93Q46493273-B3CA6C6C-026B-4DF6-955C-B7D02B9B1935Q47383863-6F632F82-2C96-48A2-B256-46AEF61C0710Q47384456-8199FF4B-87BA-4953-8003-879116A0D167Q47835108-1EE1BDAD-1851-49AD-B2F1-8D384C439BCCQ50098939-F9C7E1B8-95F3-43A5-9382-4FBF346850A7Q50209684-DD191090-0849-4FC7-88C7-BB679E27ACC3Q57413820-B907D1B3-51EA-4D2E-A338-EA0CBAB85CDAQ60750485-FE5B04FB-2454-4366-8100-9D6C7AA1B26FQ86558450-EE5C97FD-C562-442C-9258-7DD88764965BQ87310162-3F2168AF-CF8B-4BBD-9EFC-CD42597AB06DQ87988446-E11B7261-AE2F-4474-B5F3-3435ED1D96C8Q88754440-7DE39F31-461A-4F11-B050-09A90F4775FAQ89851467-20EF377B-2817-4C62-BC2B-29B1168E62BCQ91952613-31D3B158-7E32-43BB-87E2-BEC169A40AF3Q92853069-3D5A5726-1C80-4FD7-BA83-73525BD3BA77
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael M Abecassis
@ast
Michael M Abecassis
@en
Michael M Abecassis
@es
Michael M Abecassis
@nl
Michael M Abecassis
@sl
type
label
Michael M Abecassis
@ast
Michael M Abecassis
@en
Michael M Abecassis
@es
Michael M Abecassis
@nl
Michael M Abecassis
@sl
prefLabel
Michael M Abecassis
@ast
Michael M Abecassis
@en
Michael M Abecassis
@es
Michael M Abecassis
@nl
Michael M Abecassis
@sl
P106
P31
P496
0000-0001-9333-463X